JP2009235107A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009235107A5 JP2009235107A5 JP2009171142A JP2009171142A JP2009235107A5 JP 2009235107 A5 JP2009235107 A5 JP 2009235107A5 JP 2009171142 A JP2009171142 A JP 2009171142A JP 2009171142 A JP2009171142 A JP 2009171142A JP 2009235107 A5 JP2009235107 A5 JP 2009235107A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- inhibitor
- hypertension
- combination according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003839 salts Chemical class 0.000 claims 21
- 206010020772 Hypertension Diseases 0.000 claims 7
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 4
- 102000003729 Neprilysin Human genes 0.000 claims 4
- 108090000028 Neprilysin Proteins 0.000 claims 4
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 4
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 208000010125 myocardial infarction Diseases 0.000 claims 4
- 239000002461 renin inhibitor Substances 0.000 claims 4
- 229940086526 renin-inhibitors Drugs 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 229960000528 amlodipine Drugs 0.000 claims 3
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims 3
- 208000029078 coronary artery disease Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 229940123934 Reductase inhibitor Drugs 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 206010042957 Systolic hypertension Diseases 0.000 claims 2
- 239000002170 aldosterone antagonist Substances 0.000 claims 2
- 229940083712 aldosterone antagonist Drugs 0.000 claims 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 2
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 239000000480 calcium channel blocker Substances 0.000 claims 2
- 239000002934 diuretic Substances 0.000 claims 2
- 230000001882 diuretic effect Effects 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 230000009977 dual effect Effects 0.000 claims 2
- 230000008694 endothelial dysfunction Effects 0.000 claims 2
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical group C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 claims 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical group C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 108010061435 Enalapril Proteins 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 229960004530 benazepril Drugs 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 1
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical group COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 claims 1
- 229960003065 bosentan Drugs 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 230000001258 dyslipidemic effect Effects 0.000 claims 1
- 229960000873 enalapril Drugs 0.000 claims 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 1
- 229960001208 eplerenone Drugs 0.000 claims 1
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical group C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 claims 1
- 229950011548 fadrozole Drugs 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 229960002003 hydrochlorothiazide Drugs 0.000 claims 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical group C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 238000007634 remodeling Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 1
- 229960004699 valsartan Drugs 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0028151A GB0028151D0 (en) | 2000-11-17 | 2000-11-17 | Combination of organic compounds |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002542381A Division JP2004513920A (ja) | 2000-11-17 | 2001-11-15 | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013148269A Division JP6089278B2 (ja) | 2000-11-17 | 2013-07-17 | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009235107A JP2009235107A (ja) | 2009-10-15 |
| JP2009235107A5 true JP2009235107A5 (enExample) | 2012-03-22 |
Family
ID=9903412
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002542381A Withdrawn JP2004513920A (ja) | 2000-11-17 | 2001-11-15 | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 |
| JP2009171142A Withdrawn JP2009235107A (ja) | 2000-11-17 | 2009-07-22 | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 |
| JP2013148269A Expired - Lifetime JP6089278B2 (ja) | 2000-11-17 | 2013-07-17 | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 |
| JP2016214552A Expired - Lifetime JP6373931B2 (ja) | 2000-11-17 | 2016-11-01 | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 |
| JP2017232474A Expired - Lifetime JP6577994B2 (ja) | 2000-11-17 | 2017-12-04 | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 |
| JP2018103151A Expired - Lifetime JP6603757B2 (ja) | 2000-11-17 | 2018-05-30 | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002542381A Withdrawn JP2004513920A (ja) | 2000-11-17 | 2001-11-15 | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013148269A Expired - Lifetime JP6089278B2 (ja) | 2000-11-17 | 2013-07-17 | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 |
| JP2016214552A Expired - Lifetime JP6373931B2 (ja) | 2000-11-17 | 2016-11-01 | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 |
| JP2017232474A Expired - Lifetime JP6577994B2 (ja) | 2000-11-17 | 2017-12-04 | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 |
| JP2018103151A Expired - Lifetime JP6603757B2 (ja) | 2000-11-17 | 2018-05-30 | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US8168616B1 (enExample) |
| EP (7) | EP1930000A1 (enExample) |
| JP (6) | JP2004513920A (enExample) |
| KR (6) | KR20080096715A (enExample) |
| CN (4) | CN100404024C (enExample) |
| AT (2) | ATE397445T1 (enExample) |
| AU (2) | AU2002223680B2 (enExample) |
| BR (1) | BR0115411A (enExample) |
| CA (2) | CA2763223A1 (enExample) |
| CY (5) | CY1105603T1 (enExample) |
| CZ (2) | CZ305341B6 (enExample) |
| DE (3) | DE122009000021I1 (enExample) |
| DK (3) | DK1602370T3 (enExample) |
| EC (1) | ECSP034603A (enExample) |
| ES (4) | ES2429292T3 (enExample) |
| GB (1) | GB0028151D0 (enExample) |
| HU (2) | HUP0301841A3 (enExample) |
| IL (3) | IL155707A (enExample) |
| LU (2) | LU91563I2 (enExample) |
| MX (1) | MXPA03004358A (enExample) |
| NL (2) | NL300385I1 (enExample) |
| NO (2) | NO334002B1 (enExample) |
| NZ (6) | NZ568764A (enExample) |
| PL (3) | PL400915A1 (enExample) |
| PT (3) | PT1602370E (enExample) |
| RU (2) | RU2310443C2 (enExample) |
| SG (1) | SG135969A1 (enExample) |
| SI (3) | SI1915993T1 (enExample) |
| SK (1) | SK287881B6 (enExample) |
| WO (1) | WO2002040007A1 (enExample) |
| ZA (1) | ZA200303497B (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005509631A (ja) * | 2001-10-18 | 2005-04-14 | ノバルティス アクチエンゲゼルシャフト | Ａｔ１−レセプターアンタゴニストと心臓血管薬から形成される塩 |
| NZ536555A (en) * | 2002-05-17 | 2007-03-30 | Novartis Ag | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
| GB0212410D0 (en) * | 2002-05-29 | 2002-07-10 | Novartis Ag | Organic compounds |
| JP2005537822A (ja) * | 2002-06-28 | 2005-12-15 | ノバルティス アクチエンゲゼルシャフト | 有機化合物の使用 |
| AU2003255527A1 (en) * | 2002-06-28 | 2004-01-19 | Speedel Pharma Ag | Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant |
| SE0300988D0 (sv) * | 2003-04-03 | 2003-04-03 | Astrazeneca Ab | New use |
| TW200900399A (en) | 2003-10-01 | 2009-01-01 | Speedel Experimenta Ag | Organic compounds |
| GB0325605D0 (en) * | 2003-11-03 | 2003-12-10 | Novartis Ag | Combination of organic compounds |
| CN1882528A (zh) | 2003-11-26 | 2006-12-20 | 诺瓦提斯公司 | 有机化合物 |
| GB0327839D0 (en) * | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
| WO2005070871A2 (en) | 2004-01-23 | 2005-08-04 | Speedel Experimenta Ag | Amino alcohol derivatives and their activity as renin inhibitors |
| US7767690B2 (en) | 2004-01-23 | 2010-08-03 | Novartis Ag | Amino alcohol derivatives and their use as renin inhibitor |
| US7718675B2 (en) * | 2004-01-23 | 2010-05-18 | Speedel Experimenta Ag | Diamino alcohols and their use as renin inhibitor |
| NZ586285A (en) * | 2004-03-17 | 2011-12-22 | Novartis Ag | Use of aliskiren in monotherapy for treating diabetes and metabolic disorder (syndrome X) |
| PE20110121A1 (es) * | 2004-03-17 | 2011-02-28 | Novartis Ag | Composiciones farmaceuticas de aliskiren |
| CA2560195A1 (en) | 2004-03-19 | 2005-09-29 | Speedel Experimenta Ag | Organic compounds |
| WO2005099695A1 (en) * | 2004-04-19 | 2005-10-27 | Novartis Ag | Drug delivery systems for the prevention and treatment of vascular diseases |
| CN101102755B (zh) * | 2004-10-08 | 2013-01-02 | 诺瓦提斯公司 | 肾素抑制剂在制备预防或治疗舒张功能障碍或舒张性心力衰竭的药物中的用途 |
| GB0428250D0 (en) * | 2004-12-23 | 2005-01-26 | Novartis Ag | Organic compounds |
| MY146830A (en) * | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
| EP1897879A3 (en) | 2005-03-31 | 2008-06-11 | Speedel Experimenta AG | 2,4,5-substituted piperidines as renin inhibitors |
| TW200722424A (en) | 2005-03-31 | 2007-06-16 | Speedel Experimenta Ag | Substituted piperidines |
| MX2007013471A (es) * | 2005-04-27 | 2008-01-22 | Novartis Ag | Metodos de tratamiento de aterosclerosis. |
| GB0511686D0 (en) * | 2005-06-08 | 2005-07-13 | Novartis Ag | Organic compounds |
| CN1732952B (zh) * | 2005-09-02 | 2010-04-07 | 姚俊华 | 一种治疗高血压的复方分散片 |
| US8158146B2 (en) | 2005-09-28 | 2012-04-17 | Teva Pharmaceutical Industries Ltd. | Stable combinations of amlodipine besylate and benazepril hydrochloride |
| DK1797885T3 (da) * | 2005-09-28 | 2008-07-14 | Teva Pharma | Stabil kombination af amlodipinbesylat og benazeprilhydrochlorid |
| RU2008122712A (ru) * | 2005-11-08 | 2009-12-20 | Новартис АГ (CH) | Комбинация органических соединений |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| RU2008136317A (ru) * | 2006-03-13 | 2010-04-20 | Инсайсив Фармасьютикалз, Инк. (US) | Способы и композиции для лечения диагностикой сердечной недостаточности |
| US20070260203A1 (en) * | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
| GB0612540D0 (en) | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
| TW200831463A (en) * | 2006-09-12 | 2008-08-01 | Speedel Experimenta Ag | Nitrate esters of aminoalcohols |
| KR100888131B1 (ko) * | 2006-10-10 | 2009-03-11 | 한올제약주식회사 | 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제 |
| JP2010513300A (ja) * | 2006-12-15 | 2010-04-30 | ノバルティス アーゲー | 肥満患者における高血圧の予防および処置のためのレニン阻害剤 |
| EP2120899A1 (en) * | 2007-02-14 | 2009-11-25 | Gilead Colorado, Inc. | Antihypertensive drug combination |
| AR066168A1 (es) * | 2007-09-28 | 2009-07-29 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| EP2062874B1 (en) | 2007-11-20 | 2014-12-17 | KRKA, tovarna zdravil, d.d., Novo mesto | Process and intermediates for the preparation of aliskiren |
| US20110111021A1 (en) | 2008-02-22 | 2011-05-12 | Hanall Biopharma Co., Ltd. | Pharmaceutical preparation |
| US20110111022A1 (en) | 2008-04-10 | 2011-05-12 | Hanall Biopharma Co., Ltd. | Pharmaceutical formulation |
| WO2009127251A1 (en) * | 2008-04-16 | 2009-10-22 | Novartis Ag | Combinations comprising a renin inhibitor |
| EP2281557A4 (en) | 2008-04-29 | 2011-08-31 | Hanall Biopharma Co Ltd | PHARMACEUTICAL FORMULATION CONTAINING AN ANGIOTENSIN II RECEPTOR BLOCKING AGENT |
| WO2010024772A1 (en) * | 2008-08-29 | 2010-03-04 | Medivir Ab | Aspartyl protease inhibitors |
| SI2189442T1 (sl) | 2008-11-20 | 2015-03-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Postopek in intermediati za pripravo aliskirena |
| AR075880A1 (es) | 2009-03-20 | 2011-05-04 | Novartis Ag | Formulaciones galenicas de compuestos organicos que comprenden alisquireno y valsartan. uso. metodo. |
| CN101926793B (zh) * | 2010-08-05 | 2012-08-15 | 成都自豪药业有限公司 | 一种含替米沙坦和阿利吉伦的联合用药物及其制备方法 |
| WO2012152718A1 (en) | 2011-05-06 | 2012-11-15 | Farmicom Pharmaceutical Company D.O.O. | Composition comprising angiotensin ii receptor antagonist and antioxidant for maintaining and/or improving skin properties |
| RU2483750C1 (ru) * | 2012-03-19 | 2013-06-10 | Общество с ограниченной ответственностью "СупраГен" | Способ лечения больных с острым инфарктом миокарда с подъемом сегмента st |
| SG11201407200TA (en) * | 2012-05-18 | 2014-12-30 | Luoda Pharma Pty Ltd | Liquid formulation |
| RU2554815C1 (ru) * | 2014-06-18 | 2015-06-27 | Общество с ограниченной ответственностью "Нанолек" | Гипотензивное средство |
| BR112017001758A2 (pt) | 2014-07-30 | 2017-11-21 | Merck Patent Gmbh | álcoois polivinílicos diretamente compressíveis |
| CA3040803A1 (en) * | 2016-10-27 | 2018-05-03 | Damian Pharma Ag | Aldosterone synthase inhibitor |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4617307A (en) | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
| US4889861A (en) | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
| FI77669C (fi) | 1983-04-13 | 1989-04-10 | Ciba Geigy Ag | 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat. |
| US4782043A (en) | 1983-06-15 | 1988-11-01 | Merck & Co., Inc. | Renin inhibitors containing a C-terminal amide cycle |
| US4898729A (en) | 1983-12-09 | 1990-02-06 | Euroceltique, S.A. | Treatment of hypertension, compounds and compositions for antihypertension and diuresis |
| US4812442A (en) | 1984-05-29 | 1989-03-14 | Merck & Co., Inc. | Tripeptide renin inhibitors |
| CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
| US5594021A (en) | 1993-05-20 | 1997-01-14 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US4927807A (en) | 1987-10-06 | 1990-05-22 | Abbott Laboratories | Glaucoma treatment |
| SE8802428D0 (sv) * | 1988-06-28 | 1988-06-28 | Haessle Ab | New compounds |
| US5268374A (en) | 1988-10-04 | 1993-12-07 | Abbott Laboratories | Non-peptide renin inhibitors |
| US5164388A (en) | 1988-10-19 | 1992-11-17 | Abbott Laboratories | Heterocyclic peptide renin inhibitors |
| ES2142789T3 (es) | 1989-06-14 | 2000-05-01 | Smithkline Beecham Corp | Acidos imidazolil-alquenoicos. |
| EP0438311A3 (en) * | 1990-01-19 | 1992-07-01 | Merck & Co. Inc. | Di- and tripeptide renin inhibitors |
| US5182266A (en) * | 1990-01-31 | 1993-01-26 | Abbott Laboratories | Method for treating renal disease |
| IL97219A (en) * | 1990-02-19 | 1995-12-08 | Ciba Geigy Ag | Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them |
| PT97078B (pt) | 1990-03-20 | 1997-07-31 | Sanofi Sa | Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem |
| US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| US5821232A (en) | 1990-05-11 | 1998-10-13 | Pfizer Inc. | Synergistic therapeutic compositions and methods |
| IE68045B1 (en) | 1990-05-11 | 1996-05-15 | Abbott Lab | Renin inhibitors |
| RU2147875C1 (ru) * | 1990-05-11 | 2000-04-27 | Пфайзер Инк. | Способ и композиция для снижения кровяного давления и лечения застойной сердечной недостаточности у млекопитающего |
| WO1992000972A1 (en) | 1990-07-11 | 1992-01-23 | Abbott Laboratories | Renin inhibiting compounds |
| WO1992003429A1 (en) * | 1990-08-15 | 1992-03-05 | Abbott Laboratories | Renin inhibitors |
| US5656650A (en) * | 1990-12-14 | 1997-08-12 | Smithkline Beecham Corp. | Angiotensin II receptor blocking compositions |
| DE69131021T2 (de) | 1990-12-14 | 1999-08-12 | Smithkline Beecham Corp., Philadelphia, Pa. 19101 | Angiotensin-ii-rezeptor blockierende zusammensetzungen |
| AU1256692A (en) | 1991-02-06 | 1992-09-07 | Schering Corporation | Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor |
| CA2229000C (en) | 1991-02-21 | 2002-04-09 | Sankyo Company, Limited | 1-biphenylimidazole derivatives, their preparation and their therapeutic use |
| RU2086544C1 (ru) * | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
| DE4121975A1 (de) | 1991-07-03 | 1993-01-07 | Basf Ag | Thermoplastische formmassen auf der basis von polycarbonaten, styrol/acrylnitril-polymerisaten und polyolefinen |
| US5256667A (en) | 1991-09-25 | 1993-10-26 | Merck & Co., Inc. | Quinazolinones and pyridopyrimidinones |
| TW226375B (enExample) | 1991-10-24 | 1994-07-11 | American Home Prod | |
| US6057344A (en) | 1991-11-26 | 2000-05-02 | Sepracor, Inc. | Methods for treating hypertension, and angina using optically pure (-) amlodipine |
| NZ266314A (en) | 1993-04-27 | 1998-10-28 | Smithkline Beecham Corp | Various indane-2-carboxylic acid derivatives substituted by (hetero)aryl-containing moieties and various other indane derivatives as endothelian receptor antagonists and pharmaceutical compositions |
| US5508272A (en) * | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
| EP0634175B1 (de) * | 1993-07-15 | 2001-01-10 | F. Hoffmann-La Roche Ag | Pharmazeutische Kombination, die einen Hemmer des Renin-Angiotensin-Systems und einen Endothelin-Antagonisten enthält |
| DK0714897T3 (da) | 1993-08-18 | 2001-03-19 | Banyu Pharma Co Ltd | Ring-kondenseret heteroaromatisk cyclopentenderivat med endothelinantagonist-aktivitet |
| US5659065A (en) | 1994-04-18 | 1997-08-19 | Novartis Corporation | Alpha-aminoalkanoic acids and reduction products |
| US5606078A (en) | 1994-04-18 | 1997-02-25 | Ciba-Geigy Corporation | 3,5-Disubstituted tetrahydrofuran-2-ones |
| MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
| US5562921A (en) | 1994-07-15 | 1996-10-08 | Sherman; Bernard C. | Stable solid pharmaceutical compositions containing enalapril maleate |
| DE69527072T2 (de) | 1994-08-19 | 2003-02-13 | Abbott Laboratories, Abbott Park | Endothelin antagoniste |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| DE19533023B4 (de) | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| TW313568B (enExample) | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
| PL184060B1 (pl) | 1995-01-27 | 2002-08-30 | Rhone Poulenc Rorer Ltd | Podstawione związki fenylowe do zastosowania jako środki antagonistyczne endoteliny |
| US5846990A (en) | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
| JPH0971586A (ja) * | 1995-09-07 | 1997-03-18 | Yamanouchi Pharmaceut Co Ltd | 新規な二環性縮合イミダゾール誘導体 |
| US5696166A (en) | 1995-10-31 | 1997-12-09 | Yanni; John M. | Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders |
| ATE201202T1 (de) | 1995-12-20 | 2001-06-15 | Yamanouchi Pharma Co Ltd | Arylethensulfonamid-derivate und diese enthaltende medikamente |
| IT1277737B1 (it) | 1995-12-28 | 1997-11-12 | Zambon Spa | Derivati tiolici ad attivita' inibitrice delle metallopeptidasi |
| WO1997027314A1 (fr) | 1996-01-23 | 1997-07-31 | Shionogi & Co., Ltd. | Processus de production d'analogues d'acide oleanolique par la culture de racine pileuse |
| CA2249330C (en) | 1996-04-04 | 2005-08-09 | Banyu Pharmaceutical Co., Ltd. | Method of treating heart failure with endothelin antagonists |
| GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
| DE19806438A1 (de) * | 1998-02-17 | 1999-08-19 | Basf Ag | Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung |
| CA2332608C (en) * | 1998-06-17 | 2010-03-23 | Bristol-Myers Squibb Company | Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination |
| US6517871B1 (en) | 1998-07-20 | 2003-02-11 | Smithkline Beecham Corporation | Bioenhanced formulations comprising eprosartan in oral solid dosage form |
| UA74141C2 (uk) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
| JP2003511347A (ja) * | 1999-03-19 | 2003-03-25 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | ＩＩＩ型内皮細胞一酸化窒素合成酵素のＨＭＧ−ＣｏＡ還元酵素阻害物質による上方制御 |
| CA2390561A1 (en) | 1999-11-09 | 2001-05-17 | Pharmacia Corporation | Use of an aldosterone antagonist for treating restenosis |
| US20030114389A1 (en) * | 2001-11-13 | 2003-06-19 | Webb Randy Lee | Combination of organic compounds |
| NZ536555A (en) * | 2002-05-17 | 2007-03-30 | Novartis Ag | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
| ATE397147T1 (de) | 2002-12-31 | 2008-06-15 | Volkswagen Ag | Verfahren zur steuerung einer verbrennungskraftmaschine sowie magerlauffahige verbrennungskraftmaschine |
-
2000
- 2000-11-15 US US10/416,039 patent/US8168616B1/en not_active Expired - Fee Related
- 2000-11-17 GB GB0028151A patent/GB0028151D0/en not_active Ceased
-
2001
- 2001-11-15 CZ CZ2011-614A patent/CZ305341B6/cs not_active IP Right Cessation
- 2001-11-15 PT PT05015603T patent/PT1602370E/pt unknown
- 2001-11-15 EP EP20080002604 patent/EP1930000A1/en not_active Withdrawn
- 2001-11-15 SG SG200504685-9A patent/SG135969A1/en unknown
- 2001-11-15 NZ NZ568764A patent/NZ568764A/en not_active IP Right Cessation
- 2001-11-15 MX MXPA03004358A patent/MXPA03004358A/es active IP Right Grant
- 2001-11-15 PT PT01996377T patent/PT1341533E/pt unknown
- 2001-11-15 RU RU2003116896A patent/RU2310443C2/ru not_active IP Right Cessation
- 2001-11-15 NZ NZ550897A patent/NZ550897A/en not_active IP Right Cessation
- 2001-11-15 HU HU0301841A patent/HUP0301841A3/hu not_active Application Discontinuation
- 2001-11-15 KR KR1020087024051A patent/KR20080096715A/ko not_active Withdrawn
- 2001-11-15 DK DK05015603T patent/DK1602370T3/da active
- 2001-11-15 JP JP2002542381A patent/JP2004513920A/ja not_active Withdrawn
- 2001-11-15 SI SI200131026T patent/SI1915993T1/sl unknown
- 2001-11-15 NZ NZ550898A patent/NZ550898A/en not_active IP Right Cessation
- 2001-11-15 CN CNB018190685A patent/CN100404024C/zh not_active Expired - Fee Related
- 2001-11-15 PL PL40091501A patent/PL400915A1/pl unknown
- 2001-11-15 KR KR10-2003-7005901A patent/KR20030051753A/ko not_active Ceased
- 2001-11-15 KR KR1020087001407A patent/KR20080011355A/ko not_active Ceased
- 2001-11-15 AU AU2002223680A patent/AU2002223680B2/en not_active Expired
- 2001-11-15 NZ NZ550896A patent/NZ550896A/en not_active IP Right Cessation
- 2001-11-15 CA CA 2763223 patent/CA2763223A1/en not_active Withdrawn
- 2001-11-15 PT PT08002401T patent/PT1915993E/pt unknown
- 2001-11-15 NZ NZ525795A patent/NZ525795A/en not_active IP Right Cessation
- 2001-11-15 SI SI200130530T patent/SI1341533T1/sl unknown
- 2001-11-15 HU HUP1400409A patent/HU230882B1/hu not_active IP Right Cessation
- 2001-11-15 AU AU2368002A patent/AU2368002A/xx active Pending
- 2001-11-15 KR KR1020087024052A patent/KR101008752B1/ko not_active Expired - Fee Related
- 2001-11-15 EP EP20100179116 patent/EP2305233A1/en not_active Withdrawn
- 2001-11-15 CA CA 2428647 patent/CA2428647A1/en not_active Withdrawn
- 2001-11-15 SI SI200130850T patent/SI1602370T1/sl unknown
- 2001-11-15 IL IL155707A patent/IL155707A/en not_active IP Right Cessation
- 2001-11-15 DE DE200912000021 patent/DE122009000021I1/de active Pending
- 2001-11-15 WO PCT/EP2001/013241 patent/WO2002040007A1/en not_active Ceased
- 2001-11-15 CN CNA200710140212XA patent/CN101091703A/zh active Pending
- 2001-11-15 DE DE2001617295 patent/DE60117295T2/de not_active Expired - Lifetime
- 2001-11-15 CN CNA2008100985065A patent/CN101264073A/zh active Pending
- 2001-11-15 EP EP20100179101 patent/EP2305231A1/en not_active Withdrawn
- 2001-11-15 EP EP20010996377 patent/EP1341533B1/en not_active Expired - Lifetime
- 2001-11-15 CZ CZ20031341A patent/CZ299749B6/cs not_active IP Right Cessation
- 2001-11-15 EP EP10179109.3A patent/EP2305232B1/en not_active Expired - Lifetime
- 2001-11-15 ES ES08002401T patent/ES2429292T3/es not_active Expired - Lifetime
- 2001-11-15 CN CNA2008100985050A patent/CN101264072A/zh active Pending
- 2001-11-15 AT AT05015603T patent/ATE397445T1/de active
- 2001-11-15 ES ES01996377T patent/ES2256335T3/es not_active Expired - Lifetime
- 2001-11-15 EP EP20080002401 patent/EP1915993B1/en not_active Revoked
- 2001-11-15 DE DE60134349T patent/DE60134349D1/de not_active Expired - Lifetime
- 2001-11-15 BR BR0115411A patent/BR0115411A/pt not_active Application Discontinuation
- 2001-11-15 PL PL40091401A patent/PL400914A1/pl unknown
- 2001-11-15 KR KR1020107018819A patent/KR20100114904A/ko not_active Ceased
- 2001-11-15 NZ NZ537691A patent/NZ537691A/en not_active IP Right Cessation
- 2001-11-15 SK SK584-2003A patent/SK287881B6/sk not_active IP Right Cessation
- 2001-11-15 PL PL361404A patent/PL227576B1/pl unknown
- 2001-11-15 DK DK01996377T patent/DK1341533T3/da active
- 2001-11-15 EP EP20050015603 patent/EP1602370B1/en not_active Revoked
- 2001-11-15 KR KR1020117012347A patent/KR101258365B1/ko not_active Expired - Fee Related
- 2001-11-15 AT AT01996377T patent/ATE317692T1/de active
- 2001-11-15 ES ES05015603T patent/ES2308347T3/es not_active Expired - Lifetime
- 2001-11-15 DK DK08002401T patent/DK1915993T3/da active
- 2001-11-15 ES ES10179109T patent/ES2734523T3/es not_active Expired - Lifetime
-
2003
- 2003-05-07 ZA ZA200303497A patent/ZA200303497B/en unknown
- 2003-05-13 EC ECSP034603 patent/ECSP034603A/es unknown
- 2003-05-16 NO NO20032233A patent/NO334002B1/no not_active IP Right Cessation
-
2006
- 2006-04-13 CY CY20061100519T patent/CY1105603T1/el unknown
- 2006-09-12 RU RU2006132668A patent/RU2346703C2/ru not_active IP Right Cessation
-
2008
- 2008-09-02 CY CY20081100932T patent/CY1108305T1/el unknown
-
2009
- 2009-04-24 NL NL300385C patent/NL300385I1/nl unknown
- 2009-05-06 LU LU91563C patent/LU91563I2/fr unknown
- 2009-05-11 CY CY2009005C patent/CY2009005I2/el unknown
- 2009-07-22 JP JP2009171142A patent/JP2009235107A/ja not_active Withdrawn
-
2011
- 2011-03-31 IL IL212075A patent/IL212075A/en not_active IP Right Cessation
- 2011-09-19 US US13/235,787 patent/US8618174B2/en not_active Expired - Fee Related
- 2011-09-19 US US13/235,659 patent/US9023893B2/en not_active Expired - Fee Related
- 2011-09-19 US US13/235,758 patent/US9023894B2/en not_active Expired - Fee Related
-
2012
- 2012-01-30 IL IL217847A patent/IL217847A0/en unknown
-
2013
- 2013-07-17 JP JP2013148269A patent/JP6089278B2/ja not_active Expired - Lifetime
- 2013-10-10 CY CY20131100889T patent/CY1114829T1/el unknown
- 2013-11-27 LU LU92315C patent/LU92315I2/fr unknown
- 2013-12-13 CY CY2013045C patent/CY2013045I2/el unknown
- 2013-12-17 NO NO2013019C patent/NO2013019I1/no unknown
-
2016
- 2016-11-01 JP JP2016214552A patent/JP6373931B2/ja not_active Expired - Lifetime
-
2017
- 2017-12-04 JP JP2017232474A patent/JP6577994B2/ja not_active Expired - Lifetime
-
2018
- 2018-05-30 JP JP2018103151A patent/JP6603757B2/ja not_active Expired - Lifetime
-
2019
- 2019-09-06 NL NL301005C patent/NL301005I2/nl unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009235107A5 (enExample) | ||
| RU2003116896A (ru) | Синергетические композиции, которые содержат ингибитор ренина, предназначенные для лечения сердечно-сосудистых заболеваний | |
| RU2004139025A (ru) | Комбинация ингибитора дипептидилпептидазы iv (dpp iv) и сердечно-сосудистого вещества | |
| CN100404024C (zh) | 用于治疗心血管疾病的含有肾素抑制剂的协同性药物联合形式 | |
| JP2005532330A5 (enExample) | ||
| JP2004513920A5 (enExample) | ||
| EP2213668A3 (en) | Imidazoles as aldosterone synthase inhibitors | |
| WO2010099054A3 (en) | Soluble guanylate cyclase activators | |
| WO2007106708A3 (en) | Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril | |
| EP2397476A3 (en) | Indole derivative having PGD2 receptor antagonist activity | |
| CN103539791B (zh) | Gpr119 受体调节剂和对与其相关的障碍的治疗 | |
| WO2007146758A3 (en) | Novel mch receptor antagonists | |
| TW201835071A (zh) | 4-嘧啶磺醯胺衍生物之結晶形式 | |
| AU2002223680A1 (en) | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases | |
| CA2678958C (en) | Heterocyclic aspartyl protease inhibitors | |
| PL219032B1 (pl) | Kompozycja farmaceutyczna zawierająca alskiren, amlodypinę i hydrochlortiazyd, kombinacja zawierająca te składniki, zastosowanie wspomnianej kombinacji oraz zestaw handlowy zawierający wspomnianą kombinację | |
| CN102976928A (zh) | 用于降低尿酸的化合物 | |
| RU2009111378A (ru) | Терапевтические композиции, содержащие специфический антагонист рецептора эндотелина и ингибиторов pde5 | |
| CN101421231A (zh) | 阿利吉仑与硫酸的盐 | |
| FI3562487T3 (fi) | Metalloentsyymi-inhibiittoriyhdisteitä | |
| RU2008135692A (ru) | Комбинация органический х-соединений | |
| RU2008148600A (ru) | Производные бензиламина в качестве ингибиторов сетр | |
| RU2017104111A (ru) | Ингибиторы внешнего медуллярного калиевого канала | |
| AU2004204352A1 (en) | Pharmaceutical combination of telmisartan and atorvastatin for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases | |
| RU2006117790A (ru) | Применение производного пиразола для получения лекарственного средства, пригодного для профилактики и лечения дислипидемий и заболеваний, связанных с дислипидемиями и/или с ожирением |